✦ LIBER ✦

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

✍ Scribed by Gazdar, A F

Book ID: 109971000
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 213 KB
Volume: 28
Category: Article
ISSN: 0950-9232
DOI: 10.1038/onc.2009.198

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

The Potential Clinical and Economic Outc

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

✍ Josh J. Carlson; Louis P. Garrison; Scott D. Ramsey; David L. Veenstra 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

EGFR tyrosine kinase inhibitors in non-s

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

✍ Raffaele Califano; Fiona H. Blackhall; Giovanna Finocchiaro; Luca Toschi; Nichol 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 253 KB

Absence of EGFR mutation in the kinase d

Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer

✍ Jong Woo Lee; Young Hwa Soung; Su Young Kim; Won Sang Park; Suk Woo Nam; Jung Yo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 61 KB 👁 1 views

EGFR inhibitors in non-small cell lung c

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

✍ James F. Spicer; Sarah M. Rudman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 239 KB

Immediate versus delayed treatment with

Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer

✍ Zhi-jie Wang; Tong-tong An; Tony Mok; Lu Yang; Hua Bai; Jun Zhao; Jian-chun Duan 📂 Article 📅 2011 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 359 KB